DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....
ORZILOBEN,
CAS 1555822-28-0
2-methyl-3-(pentyloxy)benzoic acid
| Molecular Weight | 222.28 |
|---|---|
| Formula | C13H18O3 |
Orziloben is a medium chain fatty acid (MCFA) analogue[1]
Phase IILiver disorders
OriginatorPronova BioPharma
DeveloperNorthSea Therapeutics
ClassAntifibrotics; Hepatoprotectants; Omega 3 fatty acids; Unsaturated fatty acids
Mechanism of ActionUndefined mechanism.
28 Jan 2025No recent reports of development identified for phase-I development in Liver-disorders(In volunteers) in United Kingdom (PO)- 24 Dec 2024Chemical structure information added.
- 23 Aug 2024NorthSea Therapeutics completes a phase I trial in healthy volunteers in the United Kingdom (PO) (ISRCTN12367117)
Patent
WO2020074964
The rising global epidemic of obesity and its comorbidities, e.g., type 2 diabetes mellitus and hyperlipidemia, is placing an enormous burden both on public health (mortality and morbidity) and on the available public health resources required to treat these conditions.
Current drugs that treat hyperlipidemia (e.g., statins, omega-3 fatty acids, fibrates) have mostly neutral effects on glycemic control, whilst drugs targeting glycemic control e.g., insulin, thiazolidinediones (TZDs), have adverse effects upon bodyweight and (for TZDs) other unwanted side-effects restricting their use.
In addition to hyperlipidemia and type 2 diabetes, a marked increase in the prevalence of non-alcoholic fatty liver disease (NAFLD) has occurred. NAFLD has become the most common chronic liver condition in Western populations in relation to the obesity and type 2 diabetes epidemics. The prevalence of non-alcoholic steatohepatitis (NASH), a form of NAFLD that is associated with hepatic inflammation and ballooning of hepatocytes, is expected to increase by 63% between 2015 and 2030 in the United States (Estes, Hepatology, 2018; 67(1): 123-133), where NASH is expected to become the leading cause of liver transplantation by 2020. As liver fibrosis, but not inflammation, is associated with mortality and morbidity in NASH patients, drugs which prevent progression/induce regression of fibrosis are also a focus of biomedical research.
The development of novel compounds that simultaneously target both hyperlipidemia and glycemic control, without the adverse side-effects (e.g., weight gain) typically associated with insulin sensitising drugs is thus a desirable goal. Such compounds would be even more attractive if they could additionally prevent the progression/reverse hepatic fibrosis and reduce hepatic steatosis. The present invention addresses these needs for new treatment methods, compounds, and pharmaceutical compositions.
AS ON DEC2021 3,491,869 VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
//////////
/////////ORZILOBEN, 1555822-28-0, OBESITY, NST-6179, SEFA-6179, NST 6179, SEFA 6179
O=C(C1=C(C)C(OCCCCC)=CC=C1)O
New Drug Approvals 